References
- Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982; 49: 1796–9.
- Loth TS. Minimal surgical debridement for the treatment of chemotherapeutic agent induced skin extravasations. Cancer Treat Rep 1986; 70: 401–4.
- Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4: 41–60.
- Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12: 245–55.
- Lebredo L, Barrie R, Woltering EA. DMSO protects against adriamycin-induced tissue necrosis. J Surg Res 1992; 53: 62–5.
- Svingen BA, Powis G, Appel PL, Scott M. Protection against Adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol. Cancer Res 1981; 41: 3395–9.
- Dorr RT, Soble MJ, Liddil JD, Keller JH. Mitomycin C toxicity studies in mice: reduced ulceration and altered phar-macokinetics with topical dimethyl sulfoxide. J Clin Oncol 1986; 4: 1399–404.
- Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfox-ide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851–5.
- Langer SW, Sehested M, Jensen PB. ICRF-187 (dexrazoxane) inhibits doxorubicin-induced s.c. necrosis in mice: a new strategy in treating accidental anthracycline extravasation. Proc Am Soc Clin Oncol 1999; 18: 181a.
- Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000; 18: 3064.
- Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999; 57: 293–308.
- Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333–55.
- Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al. Preven-tion of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992; 30: 330–3.